LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2084 | 4223 | 0.4936 | 0.2421 |
| SK-BR-3 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1666 | 4223 | 0.3947 | 0.0940 |
| SK-BR-3 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4209 | 4223 | 0.9967 | 0.9951 |
| SK-BR-3 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1278 | 4223 | 0.3028 | -0.0435 |
| SK-BR-3 | BX-912 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1438 | 4223 | 0.3405 | 0.0129 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1498 | 4223 | 0.3548 | 0.0343 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1280 | 4223 | 0.3031 | -0.0431 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1231 | 4223 | 0.2915 | -0.0604 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 934 | 4223 | 0.2213 | -0.1655 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3966 | 4223 | 0.9392 | 0.9090 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2141 | 4223 | 0.5071 | 0.2622 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4261 | 4223 | 1.0091 | 1.0136 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3386 | 4223 | 0.8019 | 0.7036 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3527 | 4223 | 0.8353 | 0.7534 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3745 | 4223 | 0.8869 | 0.8307 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3339 | 4223 | 0.7907 | 0.6867 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2363 | 4223 | 0.5597 | 0.3410 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4411 | 4223 | 1.0445 | 1.0666 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4073 | 4223 | 0.9645 | 0.9468 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1448 | 4223 | 0.3429 | 0.0165 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4454 | 4223 | 1.0548 | 1.0820 |
| SK-BR-3 | Pictilisib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1695 | 4223 | 0.4015 | 0.1043 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2742 | 4223 | 0.6493 | 0.4751 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1358 | 4223 | 0.3216 | -0.0153 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1420 | 4223 | 0.3363 | 0.0067 |